sec-Butylpropylacetamide (SPD) has antimigraine properties

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Migraine affects 12-15% of the population, yet effective preventive treatments are limited.
• Valproic acid (VPA) is used for migraine prophylaxis but has a significant side effect profile.
• sec-Butylpropylacetamide (SPD) is a novel VPA derivative designed for improved potency and tolerability.

Purpose of the Study:

• To evaluate the antimigraine potential of SPD.
• To investigate SPD's mechanism of action in preclinical migraine models.

Main Methods:

• SPD's efficacy was tested in the cortical spreading depression (CSD) and nitroglycerin (NTG)-induced allodynia models.
• Whole-cell recordings were performed on cultured cortical neurons and neuroblastoma cells to assess SPD's effects on neuronal currents.

Main Results:

• SPD significantly reduced the number of CSDs in the CSD model.
• SPD dose-dependently decreased mechanical sensitivity in the NTG-induced allodynia model.
• SPD potentiated GABA-mediated currents and decreased NMDA currents, without affecting kainic acid or sodium channel currents.

Conclusions:

• SPD demonstrates significant antimigraine potential in preclinical models.
• The findings suggest a GABAergic mechanism underlies SPD's antimigraine effects.
• SPD represents a promising novel compound for migraine prevention.